243 related articles for article (PubMed ID: 36645615)
1. The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies.
Ojo AS; Araoye MO; Ali A; Sarma R
J Cancer Surviv; 2024 Jun; 18(3):673-697. PubMed ID: 36645615
[TBL] [Abstract][Full Text] [Related]
2. A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Efficace F; Boccadoro M; Palumbo A; Petrucci MT; Cottone F; Cannella L; Zamagni E; Niscola P; Kyriakou C; Caravita T; Offidani M; Mandelli F; Cavo M
Health Qual Life Outcomes; 2018 Jun; 16(1):127. PubMed ID: 29914509
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).
Chari A; Romanus D; DasMahapatra P; Hoole M; Lowe M; Curran C; Campbell S; Bell JA
Oncologist; 2019 Nov; 24(11):1479-1487. PubMed ID: 31371520
[TBL] [Abstract][Full Text] [Related]
4. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos MV; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A; Karlin L; Krishnan A; Bahlis N; Popat R; Besemer B; Martínez-López J; Delforge M; Trancucci D; Pei L; Kobos R; Fastenau J; Gries KS; van de Donk NWCJ
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):194-202. PubMed ID: 38052709
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
6. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review.
LeBlanc MR; Hirschey R; Leak Bryant A; LeBlanc TW; Smith SK
Qual Life Res; 2020 Jun; 29(6):1419-1431. PubMed ID: 31848847
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma.
Chakraborty R; Hamilton BK; Hashmi SK; Kumar SK; Majhail NS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1546-1553. PubMed ID: 29626515
[TBL] [Abstract][Full Text] [Related]
8. The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study.
Fischer J; Knop S; Danhof S; Einsele H; Keller D; Löffler C
BMC Cancer; 2022 Oct; 22(1):1032. PubMed ID: 36192719
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
10. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials.
Martino M; Rossi M; Ferreri A; Loteta B; Morabito A; Moscato T; Console G; Innao V; Naso V; Provenzano PF; Recchia AG; Gentile M
Expert Rev Hematol; 2019 Aug; 12(8):665-684. PubMed ID: 31251688
[No Abstract] [Full Text] [Related]
11. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Plesner T; Dimopoulos MA; Oriol A; San-Miguel J; Bahlis NJ; Rabin N; Suzuki K; Yoon SS; Ben-Yehuda D; Cook G; Goldschmidt H; Grosicki S; Qin X; Fastenau J; Garvin W; Carson R; Renaud T; Gries KS
Br J Haematol; 2021 Jul; 194(1):132-139. PubMed ID: 33822368
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of health-related quality of life in longitudinal studies of myeloma patients.
Nielsen LK; Jarden M; Andersen CL; Frederiksen H; Abildgaard N
Eur J Haematol; 2017 Jul; 99(1):3-17. PubMed ID: 28322018
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Delforge M; Shah N; Miguel JSF; Braverman J; Dhanda DS; Shi L; Guo S; Yu P; Liao W; Campbell TB; Munshi NC
Blood Adv; 2022 Feb; 6(4):1309-1318. PubMed ID: 34933328
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires.
Ficko SL; Pejsa V; Zadnik V
Radiol Oncol; 2019 Sep; 53(3):337-347. PubMed ID: 31553711
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.
Nielsen LK; Schjesvold F; Möller S; Guldbrandsen N; Hansson M; Remes K; Peceliunas V; Abildgaard N; Gregersen H; King MT
J Patient Rep Outcomes; 2024 Feb; 8(1):15. PubMed ID: 38315268
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.
Ahmedzai SH; Snowden JA; Ashcroft AJ; Cairns DA; Williams C; Hockaday A; Cavenagh JD; Ademokun D; Tholouli E; Allotey D; Dhanapal V; Jenner M; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Parrish C; Brown JM; Morris TCM; Cook G;
J Clin Oncol; 2019 Jul; 37(19):1617-1628. PubMed ID: 30969846
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma.
Bylund CL; Eggly S; LeBlanc TW; Kurtin S; Gandee M; Medhekar R; Fu A; Khurana M; Delaney K; Divita A; McNamara M; Baile WF
Transl Behav Med; 2023 Apr; 13(4):255-267. PubMed ID: 36688466
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life of patients with multiple myeloma: A real-world study in China.
Li X; Liu J; Chen M; Gu J; Huang B; Zheng D; Li J
Cancer Med; 2020 Nov; 9(21):7896-7913. PubMed ID: 32881377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
